Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs

We analyzed immune response to SARS-CoV-2 vaccination by measuring specific IgG titers and T-cell reactivity to different SARS-CoV-2 peptides in multiple sclerosis patients taking different disease-modifying treatments. Of the 88 patients included, 72 developed any kind of immune response after vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Meca-Lallana, Virginia, Esparcia-Pinedo, Laura, Aguirre, Clara, Díaz-Pérez, Carolina, Gutierrez-Cobos, Ainhoa, Sobrado, Mónica, Carabajal, Estefanía, Río, Beatriz del, Ropero, Noelia, Villagrasa, Ramón, Vivancos, José, Sanchez-Madrid, Francisco, Alfranca, Arantzazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2023
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898989/
https://www.ncbi.nlm.nih.gov/pubmed/38014396
http://dx.doi.org/10.1016/j.clicom.2023.02.001
_version_ 1784882548287995904
author Meca-Lallana, Virginia
Esparcia-Pinedo, Laura
Aguirre, Clara
Díaz-Pérez, Carolina
Gutierrez-Cobos, Ainhoa
Sobrado, Mónica
Carabajal, Estefanía
Río, Beatriz del
Ropero, Noelia
Villagrasa, Ramón
Vivancos, José
Sanchez-Madrid, Francisco
Alfranca, Arantzazu
author_facet Meca-Lallana, Virginia
Esparcia-Pinedo, Laura
Aguirre, Clara
Díaz-Pérez, Carolina
Gutierrez-Cobos, Ainhoa
Sobrado, Mónica
Carabajal, Estefanía
Río, Beatriz del
Ropero, Noelia
Villagrasa, Ramón
Vivancos, José
Sanchez-Madrid, Francisco
Alfranca, Arantzazu
author_sort Meca-Lallana, Virginia
collection PubMed
description We analyzed immune response to SARS-CoV-2 vaccination by measuring specific IgG titers and T-cell reactivity to different SARS-CoV-2 peptides in multiple sclerosis patients taking different disease-modifying treatments. Of the 88 patients included, 72 developed any kind of immune response after vaccination. Although DMTs such as fingolimod and anti-CD20+ treatments prevented patients from developing a robust humoral response to the vaccine, most of them were still able to develop a cellular response, which could be crucial for long-term immunity. It is probably advisable that all MS patients take additional/booster doses to increase their humoral and/or cellular immune response to SARS-CoV-2.
format Online
Article
Text
id pubmed-9898989
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-98989892023-02-06 Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs Meca-Lallana, Virginia Esparcia-Pinedo, Laura Aguirre, Clara Díaz-Pérez, Carolina Gutierrez-Cobos, Ainhoa Sobrado, Mónica Carabajal, Estefanía Río, Beatriz del Ropero, Noelia Villagrasa, Ramón Vivancos, José Sanchez-Madrid, Francisco Alfranca, Arantzazu Clinical Immunology Communications Full Length Article We analyzed immune response to SARS-CoV-2 vaccination by measuring specific IgG titers and T-cell reactivity to different SARS-CoV-2 peptides in multiple sclerosis patients taking different disease-modifying treatments. Of the 88 patients included, 72 developed any kind of immune response after vaccination. Although DMTs such as fingolimod and anti-CD20+ treatments prevented patients from developing a robust humoral response to the vaccine, most of them were still able to develop a cellular response, which could be crucial for long-term immunity. It is probably advisable that all MS patients take additional/booster doses to increase their humoral and/or cellular immune response to SARS-CoV-2. Published by Elsevier Inc. 2023-12 2023-02-04 /pmc/articles/PMC9898989/ /pubmed/38014396 http://dx.doi.org/10.1016/j.clicom.2023.02.001 Text en © 2023 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Full Length Article
Meca-Lallana, Virginia
Esparcia-Pinedo, Laura
Aguirre, Clara
Díaz-Pérez, Carolina
Gutierrez-Cobos, Ainhoa
Sobrado, Mónica
Carabajal, Estefanía
Río, Beatriz del
Ropero, Noelia
Villagrasa, Ramón
Vivancos, José
Sanchez-Madrid, Francisco
Alfranca, Arantzazu
Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs
title Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs
title_full Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs
title_fullStr Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs
title_full_unstemmed Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs
title_short Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs
title_sort analysis of humoral and cellular immunity after sars-cov-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898989/
https://www.ncbi.nlm.nih.gov/pubmed/38014396
http://dx.doi.org/10.1016/j.clicom.2023.02.001
work_keys_str_mv AT mecalallanavirginia analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs
AT esparciapinedolaura analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs
AT aguirreclara analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs
AT diazperezcarolina analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs
AT gutierrezcobosainhoa analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs
AT sobradomonica analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs
AT carabajalestefania analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs
AT riobeatrizdel analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs
AT roperonoelia analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs
AT villagrasaramon analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs
AT vivancosjose analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs
AT sanchezmadridfrancisco analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs
AT alfrancaarantzazu analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs

Ejemplares similares